ICD-10 category · Chapter XIII · M60-M79

M72 Fibroblastic disorders

73 codes under M72 in the South African Master Industry Table 2021, 43 valid for clinical use; 10 marked as a Prescribed Minimum Benefit.

Valid: the code is at its most specific level and may go on an account. Heading only: code to a more specific entry beneath it. PMB and CDL: a Prescribed Minimum Benefit or Chronic Disease List condition per the Council for Medical Schemes. † dagger and * asterisk codes are used as a pair. How to read the table
Code	Description	Use	Benefits
M72	Fibroblastic disorders	Heading only	—
M72.0	Palmar fascial fibromatosis [Dupuytren]	Heading only	—
M72.04	Palmar fascial fibromatosis [Dupuytren], hand	Valid · may be primary	—
M72.1	Knuckle pads	Heading only	—
M72.14	Knuckle pads, hand	Valid · may be primary	—
M72.2	Plantar fascial fibromatosis	Heading only	—
M72.27	Plantar fascial fibromatosis, ankle and foot	Valid · may be primary	—
M72.3	Nodular fasciitisDiscontinued in South Africa from 31 May 2013	Discontinued	—
M72.30	Nodular fasciitis, multiple sitesDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.31	Nodular fasciitis, shoulder regionDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.32	Nodular fasciitis, upper armDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.33	Nodular fasciitis, forearmDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.34	Nodular fasciitis, handDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.35	Nodular fasciitis, pelvic region and thighDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.36	Nodular fasciitis, lower legDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.37	Nodular fasciitis, ankle and footDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.38	Nodular fasciitis, other siteDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.39	Nodular fasciitis, site unspecifiedDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.4	Pseudosarcomatous fibromatosis	Heading only	—
M72.40	Pseudosarcomatous fibromatosis, multiple sites	Valid · may be primary	—
M72.41	Pseudosarcomatous fibromatosis, shoulder region	Valid · may be primary	—
M72.42	Pseudosarcomatous fibromatosis, upper arm	Valid · may be primary	—
M72.43	Pseudosarcomatous fibromatosis, forearm	Valid · may be primary	—
M72.44	Pseudosarcomatous fibromatosis, hand	Valid · may be primary	—
M72.45	Pseudosarcomatous fibromatosis, pelvic region and thigh	Valid · may be primary	—
M72.46	Pseudosarcomatous fibromatosis, lower leg	Valid · may be primary	—
M72.47	Pseudosarcomatous fibromatosis, ankle and foot	Valid · may be primary	—
M72.48	Pseudosarcomatous fibromatosis, other site	Valid · may be primary	—
M72.49	Pseudosarcomatous fibromatosis, site unspecified	Valid · may be primary	—
M72.5	Fasciitis, not elsewhere classifiedDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.50	Fasciitis, not elsewhere classified, multiple sitesDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.51	Fasciitis, not elsewhere classified, shoulder regionDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.52	Fasciitis, not elsewhere classified, upper armDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.53	Fasciitis, not elsewhere classified, forearmDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.54	Fasciitis, not elsewhere classified, handDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.55	Fasciitis, not elsewhere classified, pelvic region and thighDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.56	Fasciitis, not elsewhere classified, lower legDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.57	Fasciitis, not elsewhere classified, ankle and footDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.58	Fasciitis, not elsewhere classified, other siteDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.59	Fasciitis, not elsewhere classified, site unspecifiedDiscontinued in South Africa from 31 August 2007	Discontinued	—
M72.6	Necrotising fasciitis	Heading only	—
M72.60	Necrotising fasciitis, multiple sites	Valid · may be primary	PMB 349J Cellulitis and abscesses with risk of organ or limb damage or septiceamia if untreated; necrotizing fasciitis · Medical and surgical management
M72.61	Necrotising fasciitis, shoulder region	Valid · may be primary	PMB 349J Cellulitis and abscesses with risk of organ or limb damage or septiceamia if untreated; necrotizing fasciitis · Medical and surgical management
M72.62	Necrotising fasciitis, upper arm	Valid · may be primary	PMB 349J Cellulitis and abscesses with risk of organ or limb damage or septiceamia if untreated; necrotizing fasciitis · Medical and surgical management
M72.63	Necrotising fasciitis, forearm	Valid · may be primary	PMB 349J Cellulitis and abscesses with risk of organ or limb damage or septiceamia if untreated; necrotizing fasciitis · Medical and surgical management
M72.64	Necrotising fasciitis, hand	Valid · may be primary	PMB 349J Cellulitis and abscesses with risk of organ or limb damage or septiceamia if untreated; necrotizing fasciitis · Medical and surgical management
M72.65	Necrotising fasciitis, pelvic region and thigh	Valid · may be primary	PMB 349J Cellulitis and abscesses with risk of organ or limb damage or septiceamia if untreated; necrotizing fasciitis · Medical and surgical management
M72.66	Necrotising fasciitis, lower leg	Valid · may be primary	PMB 349J Cellulitis and abscesses with risk of organ or limb damage or septiceamia if untreated; necrotizing fasciitis · Medical and surgical management
M72.67	Necrotising fasciitis, ankle and foot	Valid · may be primary	PMB 349J Cellulitis and abscesses with risk of organ or limb damage or septiceamia if untreated; necrotizing fasciitis · Medical and surgical management
M72.68	Necrotising fasciitis, other site	Valid · may be primary	PMB 349J Cellulitis and abscesses with risk of organ or limb damage or septiceamia if untreated; necrotizing fasciitis · Medical and surgical management
M72.69	Necrotising fasciitis, site unspecified	Valid · may be primary	PMB 349J Cellulitis and abscesses with risk of organ or limb damage or septiceamia if untreated; necrotizing fasciitis · Medical and surgical management
M72.8	Other fibroblastic disorders	Heading only	—
M72.80	Other fibroblastic disorders, multiple sites	Valid · may be primary	—
M72.81	Other fibroblastic disorders, shoulder region	Valid · may be primary	—
M72.82	Other fibroblastic disorders, upper arm	Valid · may be primary	—
M72.83	Other fibroblastic disorders, forearm	Valid · may be primary	—
M72.84	Other fibroblastic disorders, hand	Valid · may be primary	—
M72.85	Other fibroblastic disorders, pelvic region and thigh	Valid · may be primary	—
M72.86	Other fibroblastic disorders, lower leg	Valid · may be primary	—
M72.87	Other fibroblastic disorders, ankle and foot	Valid · may be primary	—
M72.88	Other fibroblastic disorders, other site	Valid · may be primary	—
M72.89	Other fibroblastic disorders, site unspecified	Valid · may be primary	—
M72.9	Fibroblastic disorder, unspecified	Heading only	—
M72.90	Fibroblastic disorder, unspecified, multiple sites	Valid · may be primary	—
M72.91	Fibroblastic disorder, unspecified, shoulder region	Valid · may be primary	—
M72.92	Fibroblastic disorder, unspecified, upper arm	Valid · may be primary	—
M72.93	Fibroblastic disorder, unspecified, forearm	Valid · may be primary	—
M72.94	Fibroblastic disorder, unspecified, hand	Valid · may be primary	—
M72.95	Fibroblastic disorder, unspecified, pelvic region and thigh	Valid · may be primary	—
M72.96	Fibroblastic disorder, unspecified, lower leg	Valid · may be primary	—
M72.97	Fibroblastic disorder, unspecified, ankle and foot	Valid · may be primary	—
M72.98	Fibroblastic disorder, unspecified, other site	Valid · may be primary	—
M72.99	Fibroblastic disorder, unspecified, site unspecified	Valid · may be primary	—

Prescribed Minimum Benefits in M72. A medical scheme must fund the diagnosis, treatment and care of a PMB condition in full, within its rules on designated providers and treatment protocols. The PMB code and treatment component beside each code come from the Council for Medical Schemes’ PMB Coded List; the scheme decides whether a given claim qualifies.

Source and terms

Reproduced from the national table, unaltered.

The Department publishes the table for the industry to load. The ICD-10 Master Industry Table page

Codes and descriptions: ICD-10 Master Industry Table (MIT) 2021, published 16 March 2021 by the National Department of Health, Republic of South Africa. ® National Department of Health: all rights reserved. Reproduced for reference without alteration.

ICD-10 is the International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, © World Health Organization. The WHO ICD-10 descriptions appear as published in the MIT.

Prescribed Minimum Benefit (PMB) and Chronic Disease List (CDL) markers: Council for Medical Schemes, PMB Coded List, as read by GreenNotes. Benefit decisions rest with each medical scheme.

Source file: ICD-10_MIT_2021_Excel_16-March_2021.xlsx. Found an error in a code or description? Write to help@greennotes.co.za.

This lookup is a reference to the published code table, not coding advice. Code assignment is the treating practitioner’s responsibility, following the South African ICD-10 Coding Standards and Guidelines and the WHO ICD-10 volumes. GreenNotes does not warrant that the table is complete or current.

This is the South African table. Most ICD-10 results online are the United States’ ICD-10-CM, a different code set that South African medical schemes do not accept. Regulation 5 of the General Regulations under the Medical Schemes Act requires the diagnostic code on every account, and the Master Industry Table is the list it is coded from.

In GreenNotes

Code the consultation once. The invoice and the claim pick it up.

GreenNotes looks codes up from this same table while you write the consultation. The codes you record there, including any the clinical AI included for your review, carry into the invoice and the medical-aid claim.

Start a 14-day Clinical trial See notes become claims